Drug Profile
Batimastat ophthalmic - InSite Vision
Alternative Names: Batimastat - InSite Vision; ISV 120; ISV 615Latest Information Update: 30 May 2007
Price :
$50
*
At a glance
- Originator British Biotech
- Developer InSite Vision
- Class Aromatic amino acids; Essential amino acids; Small molecules; Thiophenes
- Mechanism of Action Collagenase inhibitors; Metalloprotease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetic retinopathy; Macular degeneration; Recurrent pterygium
Most Recent Events
- 19 Apr 2001 Discontinued-II for Recurrent pterygium in USA (Ophthalmic)
- 09 Aug 1999 Phase-I clinical trials for Macular degeneration in USA (Ophthalmic)
- 09 Aug 1999 Preclinical development for Diabetic retinopathy in USA (Ophthalmic)